Trial Profile
A Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Belimumab in Subjects With Generalized Myasthenia Gravis (MG)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Aug 2023
Price :
$35
*
At a glance
- Drugs Belimumab (Primary)
- Indications Myasthenia gravis
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 17 Apr 2018 Primary endpoint has not been met. (Change in Quantitative Myasthenia Gravis (QMG) score for Disease Severity) as per results published in the Neurology
- 17 Apr 2018 Results published in the Neurology
- 22 Jan 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.